An expert discusses how long-term follow-up data from the COMMANDS trial demonstrated sustained superiority of luspatercept ...

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for ...

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential ...

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

The ARANOTE trial (NCT04736199) represents a significant step forward in the treatment landscape for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study aimed to explore the ...

Following the FDA ODAC's vote against belantamab mafodotin-based combinations in relapsed/refractory multiple myeloma, George Mulligan, PhD, provides insight into the agent's potential path foward.

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...